Although several previous studies based on obese mice models suggested that IL-33 could reduce adiposity, induce anti-inflammation effects in adipose tissue and improve glucose and lipid metabolism [13–16, 32], there is no reports on the specific correlation between circulating level of IL-33 and human obesity and its associated metabolic disorders. Here, IL33 is linked to metabolic disease.